These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37736172)

  • 21. Imidazopyridine Compounds as ERK5 Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 Jun; 15(6):777-778. PubMed ID: 38894904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel PARP7 Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Dec; 14(12):1615-1616. PubMed ID: 38116422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel PARP1 Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Dec; 14(12):1629-1630. PubMed ID: 38116419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Furopyridine and Furopyrimidine Compounds as PI4K Inhibitors for Treating Malaria and Viral Infection.
    Sabnis RW
    ACS Med Chem Lett; 2024 Jun; 15(6):779-780. PubMed ID: 38894915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel PARP1 Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 Feb; 15(2):161-162. PubMed ID: 38352834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel ACC Inhibitors for Treating Acne.
    Sabnis RW
    ACS Med Chem Lett; 2024 Apr; 15(4):445-446. PubMed ID: 38628789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel CD73 Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 May; 15(5):571-572. PubMed ID: 38746902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel IL4I1 Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Jun; 14(6):700-701. PubMed ID: 37312856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Feb; 15(2):177-178. PubMed ID: 38352847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Phosphorylpurinone Compounds for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 Apr; 15(4):441-442. PubMed ID: 38628787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel PCSK9 Inhibitors for Treating Cardiovascular Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Apr; 15(4):443-444. PubMed ID: 38628783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel HSD17B13 Inhibitors for Treating Liver Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Jun; 15(6):771-772. PubMed ID: 38894932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Heterocyclic PAD4 Inhibitors for Treating Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Mar; 15(3):340-341. PubMed ID: 38505857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Lactams as Cbl-b Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2022 Oct; 13(10):1556-1557. PubMed ID: 36267136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Heterocyclic PAD4 Inhibitors for Treating Multiple Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Feb; 15(2):179-180. PubMed ID: 38352837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Exatecan-Derived Topoisomerase-1 Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 May; 15(5):579-580. PubMed ID: 38746899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Lactams as CBL-B Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Jul; 14(7):897-898. PubMed ID: 37465298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Diaminopyrimidine Carboxamides as HPK1 Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Jul; 14(7):899-900. PubMed ID: 37465291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nitrogen-Containing 2,3-Dihydroquinazolinone Compounds as Na
    Sabnis RW
    ACS Med Chem Lett; 2023 Jul; 14(7):893-894. PubMed ID: 37465303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fused Bicyclic Heteroaryl Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.
    Sabnis RW
    ACS Med Chem Lett; 2023 Jul; 14(7):895-896. PubMed ID: 37465294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.